osteoporosis.foundation

Scope-2021 | International Osteoporosis Foundation

“The Scorecard for Osteoporosis in Europe (SCOPE) aims to raise awareness of osteoporosis care and permits an in-depth comparison of the quality of care of osteoporosis across the region. It shows that osteoporosis is a major health care burden, resulting in enormous, and growing, costs to national health care systems...

THE SCOPE REPORT

  • Summarizes key indicators for 4 domains in the EU27 + UK and Switzerland: burden of disease, policy framework, service provision, service uptake.
  • Compares the original results from 2010 to data as recent as 2019.
  • Draws attention to the disparities in healthcare provision that can serve in the setting of benchmarks to inform patients, healthcare providers and policy makers in the EU.
  • A related SCOPE publication gives detailed country-specific metrics for each of the EU27+2 countries (please scroll down to see the country-specific resources).

Below you can view/download all resources, including the country factsheets and infographics. A webinar explaining the SCOPE 2021 findings can also be viewed.

REPORT AND RESOURCES

If sharing data or information from the SCOPE 2021 publications and resources,  please reference as:
Kanis JA, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe, Arch Osteoporos 2021 Data from SCOPE 2021 resources, International Osteoporosis Foundation https://www.osteoporosis.foundation/scope-2021

Illustrated summary report

COUNTRY-SPECIFIC SUMMARY REPORTS AND RESOURCES

If sharing data or information from the SCOPE 2021 publications and resources,  please reference as:
Kanis JA, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe, Arch Osteoporos 2021 Data from SCOPE 2021 resources, International Osteoporosis Foundation https://www.osteoporosis.foundation/scope-2021

SCOPE was supported by an unrestricted grant from Amgen.

Amgen was neither involved in the design nor writing of the report and other resources.

SCOPE Dissemination & Communication was supported by an unrestricted grant from Amgen & UCB